Journals / İzmir Dr. Behçet Uz Çocuk Hastanesi Dergisi / 2011 / Cilt: 1 - Sayı: 1

Pediatrik tümörlerde C-KİT ekspresyonu: Buzdağının altında saklı olan ne?

C-KIT expression in pediatric tumors: What is hidden beneath the tip of the iceberg?

Pages
26–32
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: Since Wilms tumor, rhabdomyosarcoma, hepatoblastoma, and nasopharingeal carcinomas express c-kit, this marker may represent a new suitable therapeutic target for these pediatric tumors.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: C-kit protein is a member of the type III receptor tyrosine kinase family.
📊
Key Findings & Data:Methods: C-kit expression was retrospectively evaluated by immunohistochemical method in 205 pediatric tumors.
💡
Conclusion & Impact:Conclusion: Since Wilms tumor, rhabdomyosarcoma, hepatoblastoma, and nasopharingeal carcinomas express c-kit, this marker may represent a new suitable therapeutic target for these pediatric tumors.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: C-kit protein is a member of the type III receptor tyrosine kinase family. Although c-kit is believed to have a pathogenetic role in gastrointestinal stromal tumors (GIST), it is expressed by several other tumors. The aim of this study is to evaluate c-kit expression in pediatric tumors. Methods: C-kit expression was retrospectively evaluated by immunohistochemical method in 205 pediatric tumors. A chi-square test was used to analyze the c-kit expression in different tumor groups. Results: Expression of c-kit is demonstrated in 9.8% of our pediatric tumor cases. C-kit is mostly expressed in Wilms tumor (in 9 cases of 32). Three of the 26 rhabdomyosarcoma cases were positive for c-kit. In three of 7 cases with hepatoblastoma, 2 of 3 cases of three inflamatory fibrous tumor, one of two nasopharingeal carcinomas, one epitheloid sarcoma, hepatocellular carcinoma and pancreatic pseudopapillary tumor c-kit was positive. Conclusion: Since Wilms tumor, rhabdomyosarcoma, hepatoblastoma, and nasopharingeal carcinomas express c-kit, this marker may represent a new suitable therapeutic target for these pediatric tumors.

Özet

Amaç: C-kit, tip 3 reseptör tirozin kinaz ailesini üyesi bir proteindir. Gastrointestinal stromal tümör patogenezinde rolü olduğuna inanılmakla birlikte, birçok başka tümörde de eksprese edilmektedir. Bu çalışmanın amacı pediatrik tümörlerde c-kit ekspresyonunu değerlendirmektir. Yöntemler: C-kit ekspresyonu immün histokimyasal boyamalarla 205 pediatrik tümörde retrospektif olarak değerlendirilmiştir. Farklı tümörlerdeki c-kit ekspresyonunun değerlendirilmesinde ki-kare testi kullanılmıştır. Bulgular: Pediatrik tümör olgularının %9,8’inde c-kit ekspresyonu gözlenmiştir. En yoğun c-kit ekspresyonu gözlenen tümör Wilms tümörüdür (32 olgunun 9’unda). Yirmi altı rabdomyosarkom olgusunun 3’ünde c-kit pozitiftir. Yedi hepatoblastomun 3’ünde, 3 inflamatuvar fibröz tümörün 2’sinde, 2 nazofarinks karsinomunun birinde, 1 epiteloid sarkomda, 1 hepatosellüler karsinomda ve 1 pankreatik psödopapiller tümörde c-kit pozitif bulunmuştur. Sonuç: Ekspresyon saptanan Wilms tümörü, rabdomyosarkom, hepatoblastom ve nazofarenks karsinomunda; pediatrik tümörlerdeki tedavi protokolleri için, c-kit yeni bir hedef oluşturabilir.

🔖

Cite This Article

AKTAŞ, S., DİNİZ, G. (2011). Pediatrik tümörlerde C-KİT ekspresyonu: Buzdağının altında saklı olan ne?. İzmir Dr. Behçet Uz Çocuk Hastanesi Dergisi, Cilt: 1 - Sayı: 1, 26–32. https://ajindex.com/articles/268727

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (10)

  1. Cypriano MS, Jenkins JJ, Pappo AS, Rao BN, Daw NC. Pediatric gastrointestinal stromal tumors and leiomyosarcoma. Cancer 2004
  2. 101(1):39-50. http://dx.doi.org/10.1002/cncr.20352 PMid:15221987 2. Legitimo A, Consolini R, Cocito MG, Buffoni R, Basso G, Macchia P. The c-kit receptor and its ligand stem cell factor in childhood malignant lymphoid precursors. J Interferon Cytokine Res 1999
  3. 19(9):981-7. http://dx.doi.org/10.1089/107999099313172 3. Miettinen M, Lasota J. Gastrointestinal stromal tumors – definition, clinical, histological, immunhistochemical, and molecular genetic features and differential diagnosis Virchows Arch 2001
  4. http://dx.doi.org/10.1007/s004280000338 PMid:11213830 4. Hasegawa T, Matsuno Y et al. Gastrointestinal stromal tumor: Consistent CD 117 immunstaining for diagnosis, and prognostic classification based on tumor size and MIB -1 grade. Hum Pathol 2002
  5. http://dx.doi.org/10.1053/hupa.2002.124116 PMid:12152168 5. Gonzalez I, Andreu EJ, Panizo A, Inoges S, Fontalba A, Fernandez-Luna JL, Gaboli M, Sierrasesumaga L, Martin-Algarra S, Pardo J, Prosper F, de Alava E. Imatinib inhibits proliferation of Ewing tumor cells mediated by the stem cell factor/KIT receptor pathway, and sensitizes cells to vincristine and doxorubicin-induced apoptosis. Clin Cancer Res 2004
  6. 10(2):751-61. http://dx.doi.org/10.1158/1078-0432.CCR-0778-03 PMid:14760098 6. Uziel O, Fenig E, Nordenberg J, Beery E, Reshef H, Sandbank J, Birenbaum M, Bakhanashvili M, Yerushalmi R, Luria D, Lahav M. Imatinib mesylate (Gleevec) downregulates telomerase activity and inhibits proliferation in telomerase-expressing cell lines. Br J Cancer 2005
  7. 92(10):1881-91. http://dx.doi.org/10.1038/sj.bjc.6602592 PMid:15870711 PMCid:2361771 7. Ahmed A, Gilbert-Barness E, Lacson A. Expression of c-kit in Ewing family of tumors: a comparison of different immunohistochemical protocols. Pediatr Dev Pathol 2004
  8. 7(4):342-347. PMid:15383930 8. Merchant MS, Woo CW, Mackall CL, Thiele CJ. Potential use of imatinib in Ewing’s Sarcoma: evidence for in vitro and in vivo activity. J Natl Cancer Inst 2002
  9. 94(22):1673-9. PMid:12441322 9. Beppu K, Jaboine J, Merchant MS, Mackall CL, Thiele CJ. Effect of imatinib mesylate on neuroblastoma tumorigenesis and vascular endothelial growth factor expression. J Natl Cancer Inst 2004
  10. 96(1):46-55. http://dx.doi.org/10.1093/jnci/djh004 10. Vitali R, Cesi V, Nicotra MR, McDowell HP, Donfrancesco A, Mannarino O, Natali PG, Raschella G, Dominici C. c-Kit